Q4 2024 Management View CEO Martin Lyons highlighted strong operational and financial results for 2024, including adjusted earnings of $4.63 per share, exceeding the midpoint of their guidance range.
1d
Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback